Loading company…
Singapore-based Travecta Therapeutics develops drug delivery systems aimed at improving the bioavailability of therapeutic compounds.
Founded in 2017 in Singapore, Travecta Therapeutics develops drug delivery systems that improve the bioavailability and efficacy of small molecules and biologics. Its clients include pharmaceutical companies and research institutions working in oncology, neurology and metabolic diseases. In September 2022 it raised USD 5.25 mn in Series A funding, its third deal, and reported 2021 revenue of USD 112,500 with an EBITDA loss of USD 7,601,780.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in